STOCK TITAN

Johnson & Johnson - JNJ STOCK NEWS

Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.

Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.

In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.

Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.

With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.

Rhea-AI Summary
Johnson & Johnson announces the resignation of Ashley McEvoy, Executive Vice President, Worldwide Chairman of MedTech, and the appointment of Tim Schmid as her replacement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
Rhea-AI Summary
Johnson & Johnson declares cash dividend for Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
dividends earnings
-
Rhea-AI Summary
Johnson & Johnson reports 6.8% sales growth in Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
Rhea-AI Summary
Johnson & Johnson to host conference call to review Q3 results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
conferences earnings
-
Rhea-AI Summary
Johnson & Johnson updates brand to showcase healthcare innovation and unite its medtech and pharmaceutical segments under one brand name.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
none
-
Rhea-AI Summary
Johnson & Johnson expects increased 2023 Reported Sales Growth of 7.0% - 8.0% and Adjusted Operational Sales Growth of 6.2% - 7.2%. They also expect 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00 - $10.10. The company reduced outstanding share count by approximately 191 million. They secured $13.2 billion in cash proceeds from the Kenvue debt offering and initial public offering. Johnson & Johnson maintains its quarterly dividend of $1.19 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
none
Rhea-AI Summary
Johnson & Johnson announced the final results of its exchange offer with Kenvue Inc. Johnson & Johnson accepted 190,955,436 shares of its common stock in exchange for 1,533,830,450 shares of Kenvue common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
-
Rhea-AI Summary
Johnson & Johnson to participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
conferences
-
Rhea-AI Summary
Johnson & Johnson's exchange offer for Kenvue common stock was oversubscribed, with approximately 23.8% of tendered shares expected to be exchanged. Shareholders with fewer than 100 shares will not be subject to proration. Johnson & Johnson will retain approximately 9.5% of Kenvue common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
none
Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) has announced the final exchange ratio for its split-off exchange offer to shareholders. For each share of Johnson & Johnson common stock tendered and accepted, the company will deliver 8.0324 shares of Kenvue Inc. common stock. Johnson & Johnson expects to accept approximately 190,955,436 shares if the offer is fully subscribed. The exchange offer is scheduled to expire on August 18, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
none

FAQ

What is the current stock price of Johnson & Johnson (JNJ)?

The current stock price of Johnson & Johnson (JNJ) is $154 as of November 15, 2024.

What is the market cap of Johnson & Johnson (JNJ)?

The market cap of Johnson & Johnson (JNJ) is approximately 353.3B.

What are the main business segments of Johnson & Johnson?

Johnson & Johnson operates through three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products.

What recent developments have there been in Johnson & Johnson's pharmaceutical division?

Recently, Johnson & Johnson received expanded FDA approval for CARVYKTI®, a therapy for multiple myeloma, based on positive Phase 3 study results.

What products are included in Johnson & Johnson’s consumer health segment?

The consumer health segment includes products in baby care, beauty, oral care, over-the-counter drugs, and women's health.

What is CARVYKTI®?

CARVYKTI® is a one-time infusion therapy for multiple myeloma, recently approved for expanded use due to its efficacy in delaying disease progression.

What percentage of Johnson & Johnson's revenue is generated in the United States?

Over half of Johnson & Johnson’s total revenue is generated in the United States.

What is the focus of Johnson & Johnson’s medical devices segment?

The medical devices segment focuses on orthopedics, surgical instruments, and vision care.

What changes are happening with Johnson & Johnson’s consumer health division?

The consumer health division is being divested in 2023 and will operate under the new name Kenvue.

How does Johnson & Johnson contribute to global healthcare?

Johnson & Johnson develops innovative solutions to prevent, treat, and cure complex diseases, aiming to improve global health.

Where can I find more information about Johnson & Johnson?

More information about Johnson & Johnson can be found on their official website at www.jnj.com.

What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?

The pharmaceutical division focuses on immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases.

Johnson & Johnson

NYSE:JNJ

JNJ Rankings

JNJ Stock Data

353.35B
2.41B
0.09%
72.76%
0.78%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NEW BRUNSWICK